RxDoctor Payments DataLook up a doctor →

John Hamm, MD

Medical Oncology · Louisville, KYNPI 1023075660

Payments from drug & device makers

$3,246,149in general payments, 2019–2025

Across 615 payments — averaging $5278.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$964K
  • AstraZeneca$508K
  • Biontech SE$247K
  • Boehringer Ingelheim International GmbH$227K
  • Amgen$197K
  • Seagen Inc.$184K
  • plus $920K from 24 others
$4,168in research payments, 2019–2025

Across 10 payments — averaging $416.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$3K
  • F. Hoffmann-la Roche AG$1K
  • AbbVie$92
  • Eli Lilly$26

What the payments were for

  • Consulting fees$7,19427%
  • Speaking & faculty fees$15,15558%
  • Travel & lodging$2,4519%
  • Food & beverage$1,4335%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,246,149 in reported general payments places this provider in the 90th percentile of 53 medical oncology providers in Kentucky.

See all medical oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$102,077
Medicare patients
246
Services billed
1,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib40$582,992
RevlimidLenalidomide22$464,500
TagrissoOsimertinib Mesylate13$221,099
LumakrasSotorasib12$202,732
JakafiRuxolitinib Phosphate11$193,062
Everolimus13$33,408
EliquisApixaban38$26,221
Ondansetron Hcl138$3,726
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen44$1,810
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen67$1,147
Morphine Sulfate ErMorphine Sulfate15$732
Dexamethasone70$620
Megestrol Acetate12$540
Levothyroxine Sodium64$474
Pantoprazole Sodium65$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$963,581$609,21278 claims
Bristol Myers SquibbRevlimid$10,245$464,50022 claims
AstraZenecaTagrisso$508,194$221,09913 claims
AmgenLumakras$196,542$202,73212 claims
Incyte CorporationJakafi$9,198$193,06211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 53 medical oncology providers in Kentucky.

Other medical oncology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →